- Asked by: Nicola Sturgeon, MSP for Glasgow Southside, Scottish National Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Gillian Martin on 18 September 2024
To ask the Scottish Government how it is monitoring the supply chain development statements submitted by ScotWind developers as part of their option agreement applications, and what action it will take in the event that any commitments are not delivered.
Answer
The Scottish Government is committed to maximising the economic opportunity for the Scottish supply chain from our offshore wind potential. We expect developers to honour their commitments set out in the Supply Chain Development Statements (SCDS) which were a condition of their being awarded Option Agreements.
The SCDS process has been carefully designed and is managed by Crown Estate Scotland (CES) to ensure focus is maintained on supply chain capacity and capability to develop and deliver offshore wind projects in Scotland.
The ScotWind SCDS were updated within 12 months of signing the Option Agreement, and must be updated at least once every 3 years thereafter. The first updates made in 2023 have resulted in an increase from £1.4 billion to £1.5 billion in projected average spend per project.
Failure by developers to deliver on their commitments can trigger remedies ranging from financial penalties to an inability to progress to a seabed lease.
- Asked by: Pam Gosal, MSP for West Scotland, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government what discussions it has had with healthcare providers regarding reducing any prolonged diagnosis times for individuals with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD).
Answer
Clinical geneticists are represented on Scotland’s Rare Disease Implementation Board (RDIB) where issues around the referral and diagnosis of individuals with hEDS and HSD have been discussed. RDIB are responsible for overseeing the implementation of Scotland’s Action Plan for Rare Diseases (2022) and the priorities for the coming year set out in our recent Progress Report (August 2024). Faster diagnosis remains one of these priorities, for all rare conditions.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Siobhian Brown on 18 September 2024
To ask the Scottish Government whether it carried out an Island Communities Impact Assessment in advance of the reported end of grant funding agreements for advice services in the Western Isles on 31 March 2024, and, if this is not the case, for what reason.
Answer
An Island Communities Impact Assessment has been carried out and will be published on the Scottish Government’s website The Scottish Government - gov.scot (www.gov.scot) by the end of September 2024. The current grant funding provision for the Western Isles Advice Project which is part of the Scottish Legal Aid Board’s Early Resolution and Advice Programme, will continue under the existing criteria for funding until 30 September 2024.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe fingolimod (Gilenya) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe diroximel fumarate (Vumerity) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe Rebif (beta interferon-1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe cladribine (Mavenclad) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe ozanimod (Zeposia) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe glatiramer acetate (Copaxone) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe siponimod (Mayzent) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.